Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase I/IIa, Open-label, Multicenter Trial to Evaluate the Safety and Efficacy of oNKord®, an Off-the-shelf, ex Vivo-cultured Allogeneic NK Cell Preparation, in Subjects With Acute Myeloid Leukemia Who Are in Morphologic Complete Remission With Measurable Residual Disease and Who Are Currently Not Proceeding to Allogeneic Hematopoietic Stem Cell Transplantation

NCT04632316 is registered in ClinicalTrials.gov with Glycostem Therapeutics BV as lead sponsor.

NCT NCT04632316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04632316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase I/IIa, Open-label, Multicenter Trial to Evaluate the Safety and Efficacy of oNKord®, an Off-the-shelf, ex Vivo-cultured Allogeneic NK Cell Preparation, in Subjects With Acute Myeloid Leukemia Who Are in Morphologic Complete Remission With Measurable Residual Disease and Who Are Currently Not Proceeding to Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Glycostem Therapeutics BV
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 8, 2020
Completion date
April 30, 2023
Enrollment
33 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia